Catalysts / VSTM
Upcoming FDA decisions and readouts we track for Verastem Oncology, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Verastem Oncology (VSTM, listed on Nasdaq). They cover 2 programmes: VS-7375 (KRAS G12D-mutant solid tumours) and Avutometinib + defactinib (Recurrent low-grade serous ovarian cancer).
First on the list: the Clinical readout for VS-7375 (KRAS G12D-mutant solid tumours), guided by the company to Oct 2026. By stage, the upcoming rows are 1 Phase 3 readout and 1 Clinical readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Verastem Oncology VSTM · Nasdaq | VS-7375 | KRAS G12D-mutant solid tumours | Oct 2026 company guidance |
Clinical readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Verastem Oncology VSTM · Nasdaq | Avutometinib + defactinib | Recurrent low-grade serous ovarian cancer | Mid 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList